MEDI 565

Drug Profile

MEDI 565

Alternative Names: AMG-211; anti-CEA BiTE; Anti-CEA BiTE mAb; CEA BiTE mAb; MEDI-565; MT-111

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen; MedImmune; University Medical Center Groningen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Carcinoembryonic antigen inhibitors; CD3 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastrointestinal cancer

Most Recent Events

  • 20 Jun 2016 Phase-I/II clinical trials in Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in Netherlands (IV) (EudraCT2015-004370-14)
  • 01 Jan 2015 MedImmune and Micromet complete a phase I trial in Gastrointestinal cancer (Late-stage disease) in USA (NCT01284231)
  • 01 Dec 2014 Phase-I clinical trials in Gastrointestinal cancer (Late-stage disease, Second-line therapy or greater) in Netherlands (IV) (NCT02291614) after December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top